Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
1.100
-0.010 (-0.90%)
At close: Dec 24, 2025, 4:00 PM EST
1.110
0.00 (0.00%)
Pre-market: Dec 26, 2025, 8:00 AM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $493.10K in the quarter ending September 30, 2025, a decrease of -85.58%. This brings the company's revenue in the last twelve months to $4.49M, up 1.51% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$4.49M
Revenue Growth
+1.51%
P/S Ratio
0.48
Revenue / Employee
$560,997
Employees
8
Market Cap
4.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ENSC News
- 14 days ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 17 days ago - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Accesswire
- 24 days ago - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 5 weeks ago - Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - Accesswire
- 5 weeks ago - Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - Accesswire
- 5 weeks ago - Ensysce Biosciences Reports Third Quarter 2025 Financial Results - Accesswire
- 2 months ago - Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 - Accesswire
- 4 months ago - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium - Accesswire